Back

Primary care detection reveals substantial cumulative LDL-C exposure in underrecognized heterozygous FH

29 August 2026 (15:15 - 16:00)
Organised by: Logo
Congress Presentation Part of: Clinico-metabolic phenotyping and heart disease (2) Biomarkers ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Hristina Leskaroska

Skopje (North Macedonia)

6 More presentations in this session

Presentation thumbnail
Clinico-metabolic phenotyping predicts long-term mortality in at-risk and pre-clinical heart failure: a machine learning analysis
Miss A. Mavromanoli (Mainz, DE)
Abstract
Presentation thumbnail
Understanding and predicting CVD in Singapore: socioeconomic determinants and a non-lab risk score across two cohorts
Professor D. Hausenloy (Singapore, SG)
Abstract
Presentation thumbnail
Prediction and cumulative incidence of in-hospital bleeding among acutely ill medical patients receiving pharmacologic VTE prophylaxis based on the IMPROVE-BRS: a retrospective single-center cohort
Doctor J. Catangui (Manila, PH)
Abstract
Presentation thumbnail
The clinical value of estimated small dense LDL in primary and secondary prevention
Doctor D. Delialis (Athens, GR)
Abstract
Presentation thumbnail
Incremental value of ADMA beyond classical risk factors for cardiometabolic risk prediction in ischemic heart disease
Doctor S. Akhmedov (Tashkent, UZ)
Abstract

Access the full session

Session thumbnail
Clinico-metabolic phenotyping and heart disease (2)

The Event

Event poster

ESC Congress 2026

29 August 2026 15:15 CET
You may be interested in
thumbnail
Congress Presentation
Predictors of cardiovascular disease in a familial hypercholesterolemia unit
13 April 2023
thumbnail
Congress Presentation
LDC-c: new insights into its role as causal risk factor and target for therapy
26 August 2022
thumbnail
Congress Presentation
Review on clinical strategies for managing patients with elevated Lp(a): Cost-effectiveness of Lp(a) testing and awareness of lifestyle changes via Public Health Policy in absence of targeted therapy
24 June 2023
thumbnail
Congress Presentation
Evolocumab rapidly reverses impaired coronary endothelial function in six weeks in people living with HIV and in patients with dyslipidemia
2 September 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources